Iron Mountain Inc vs Eli Lilly And Co — how do they compare? Iron Mountain Inc trades at $122.75 (market cap $36.19B), while Eli Lilly And Co trades at $1,214.12 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 30.4× Iron Mountain Inc's market cap, and Iron Mountain Inc pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| IRM | LLY | |
|---|---|---|
Market Cap | $36.19B | $1.10T |
Sector | Real Estate | Health |
52-Week High | $133.06 | $1.24K |
52-Week Low | $78.86 | $639.43 |
Enterprise Value | $55.60B | $1.14T |
Dividend Yield | 2.84% | 0.56% |
Signals from Pluang's Aura AI — not financial advice
Iron Mountain (IRM) trades at $121.15, down 0.66% on the day, amid a bearish technical signal. The company reported strong Q2 2026 results with revenue up 19% year-over-year to $2.03 billion, beating estimates, and has a consensus analyst price target of $141.50. However, high debt levels and a negative shareholder equity position present fundamental concerns.
Outlook is mixed: robust data center and digital growth support upside, but elevated valuation ratios and rising debt-to-asset ratios pose risks. Analyst sentiment is predominantly buy-rated (65%), yet technical indicators suggest near-term caution. Investors should weigh strong operational performance against financial leverage and market volatility.
Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.
Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.
Trailing returns across standard periods
Latest headlines on both assets
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →